Jubilant Pharmova Limited announced that Dr. Jaidev Rajpal will join the company as head of its Generics business effective from October 11, 2022. Jaidev is being appointed as Managing Director & CEO of the company's wholly owned subsidiary, Jubilant Generics Limited which is involved in the development, manufacturing and distribution of formulations to the US and Non-US markets and is also involved in the India Branded Pharmaceuticals business. Jaidev has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets.

He has a track record of delivering business transformation projects. He joins the company from McKinsey & company where he is working as a Partner in the Pharmaceuticals and Life Sciences practice. Jaidev's appointment will help the company in transforming its Generics business through commercial and operations excellence including portfolio and R&D rebalancing.

With this appointment, Jaidev will take over the Generics business from Mr. Pramod Yadav, who will continue to be the CEO of the Specialty Pharma (Radiopharma and Allergy Immunotherapy) and CDMO-Sterile Injectables businesses.